<DOC>
	<DOC>NCT00195520</DOC>
	<brief_summary>To evaluate the tolerability, bleeding patterns and acceptability of Totelle® 1mg administered to a population of Brazilian women in a continuous combined regime for hormone replacement therapy.</brief_summary>
	<brief_title>Study Evaluating Totelle® in Menopausal Symptoms and Sexual Function</brief_title>
	<detailed_description />
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Sleep Wake Disorders</mesh_term>
	<mesh_term>Parasomnias</mesh_term>
	<criteria>Intact uterus Generally health postmenopausal women 45 to 60 years of age, inclusive Sexually active No hormone replacement therapy within the 90 days immediately prior to the screening evaluation. Known or suspect estrogendependent neoplasia Known hypersensitivity to estrogens, progestins, or other ingredients of Totelle Use of any estrogen, progestin, androgen containing medications or tibolone within 12 weeks before screening.</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Sleep Disorder</keyword>
	<keyword>Hot Flashes</keyword>
</DOC>